Dissemination (Meeting Coverage)

Key risk factors for progression independent of relapse activity in relapsing-remitting MS include age and longer disease duration.

More targeted, higher efficacious medications can drastically reduce the risk for accruing disability in newly diagnosed patients with MS.

For patients with primary progressive MS, age is a particularly important factor that predicts disease activity.

The benefits of interleukin inhibitors vary by agent and include increased drug survival and earlier attainment of Psoriasis Area Severity Index scores.

Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.

Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.

Dermatologists must be knowledgeable about differences among people of color with psoriasis and to tailor their approach to diagnosis and treatment accordingly.

“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”

Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.

Check out the key presentations from AAN Fall Clinical on MS. And follow along for more from AAN.

Educational and research gaps in treating plaque psoriasis in patients with skin of color can lead to delays in diagnosis and treatment.